CBAY News and Press, CymaBay Therapeutics Inc. From 02/17/21

Today, we are posting a deep dive on CymaBay Therapeutics, one of the most volatile small-cap biotech names in the market. CymaBay's main drug candidate looks on its way to garnering FDA approval for primary biliary cholangitis. An analysis on CymaBay and what might be ahead for t...

NEWARK, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the SVB Leer...

The following slide deck was published by CymaBay Therapeutics, Inc. in conjunction with this event. For further details see: CymaBay Therapeutics (CBAY) Presents At AASLD 2020 Conference- Slideshow

Seladelpar demonstrated anti-cholestatic, anti-inflammatory, and anti-pruritic activity through 3 and 6 months Results highlight the potential for seladelpar to offer patients an efficacious and safe second line treatment option Global 52-week Phase 3 registrat...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...

The FDA lifted all holds on all CymaBay liver disease studies back in July, since, shares have begun clawing back, +319% upside YTD. The company has presented positive top-line data from the ENHANCE study for Seladelpar, which shows high conversion potential in a complex chronic disea...

The following slide deck was published by CymaBay Therapeutics, Inc. in conjunction with their 2020 Q3 earnings call. For further details see: CymaBay Therapeutics, Inc. 2020 Q3 - Results - Earnings Call Presentation

CymaBay Therapeutics, Inc. (CBAY) Q3 2020 Earnings Conference Call November 05, 2020 04:30 PM EST Company Participants Dan Menold - VP of Finance Sujal Shah - CEO Chuck McWherter - CSO Klara Dickinson - CRO Conference Call Participants Yasmeen Rahimi - Piper Sandler Steve Seedhouse - Raymond ...

Image source: The Motley Fool. CymaBay Therapeutics Inc. (NASDAQ: CBAY) Q3 2020 Earnings Call Nov 05, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: CymaBay Therapeutics Inc. (CBAY) Q3 2020 Earnings Call Transcript...

CymaBay announces trial design for RESPONSE , a global phase 3 registration stud y for seladelpar in primary biliary cholangitis (PBC) Results from the ENHANCE phase 3 study evaluating seladelpar for PBC to be featured in an oral ...